Oramed Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes; ORMD-0801, Phase 2 oral insulin capsule for non-alcoholic steatohepatitis, a progressive liver diseases; and ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York. Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD-0801 Type 2, an orally ingestible insulin c Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
EPS was $1.26 (reported).
EPS
$1.26
reported
What changed
- EPS reported to $1.26.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
QUARTERLY REPORT
Aug 10, 2026
SEC filing
QUARTERLY REPORT
May 19, 2026
SEC filing
ANNUAL REPORT
Mar 26, 2026
SEC filing
CURRENT REPORT
Nov 17, 2025
SEC filing
QUARTERLY REPORT
Nov 13, 2025
SEC filing
SHAREHOLDER LETTER, DATED OCTOBER 23, 2025
Oct 24, 2025
SEC filing
QUARTERLY REPORT
Aug 14, 2025
SEC filing
AMENDMENT NO. 1 TO FORM 10-K
Jul 16, 2025
SEC filing
QUARTERLY REPORT
May 15, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
No qualified company news in the last 14 days
No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.